Quantcast

Latest The City of London Migraine Clinic Stories

2010-04-07 15:30:00

MOUNTAIN VIEW, Calif., April 7 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX(TM) orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment...

2010-02-18 12:25:26

Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers Chronic migraine sufferers tend to be in poorer general health, less well off, and more depressed than those with episodic migraine, reveals research published ahead of print in the Journal of Neurology Neurosurgery and Psychiatry. The findings are based on almost 12,000 adults with episodic - a severe headache on up to 14 days of the month - or chronic migraine - headache on 15 or more days of the...

ba101bcadbd7d18d8b0e6c707ac1b1c41
2010-02-17 07:20:00

Migraine is seen more frequently in women with multiple sclerosis (MS) than those without, according to a study released Feb. 16 that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010. "While having a history of migraine diagnosis was linked to MS, women with migraine need to know that over 99 percent of them will never develop MS, thus having migraine should definitely not be a reason to worry about getting MS," said study...

2010-02-16 13:59:31

Migraine headache affects many people and a number of different preventative strategies should be considered, states an article in CMAJ (Canadian Medical Association Journal). The article, a primer for physicians, outlines various treatments and approaches for migraine headaches. Migraine headache is a common, disabling condition. When migraine headaches become frequent, therapy can be challenging. Preventative therapy for migraines remains one of the more difficult aspects, as while there...

9a7e1254287088e549a683304e6cf3f91
2010-02-11 11:05:00

Doctors urged to manage cardiovascular risk factors of migraine sufferers Migraine sufferers are twice as likely to have heart attacks as people without migraine, according to a new study by researchers at Albert Einstein College of Medicine of Yeshiva University. The study, published in the February 10 online issue of Neurology, found that migraine sufferers also face increased risk for stroke and were more likely to have key risk factors for cardiovascular disease, including diabetes, high...

2010-01-26 07:07:00

WALTHAM, Mass., Jan. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Zogenix/Astellas Pharma/Desitin Pharmaceuticals' needle-free Sumavel DosePro, which launched earlier this month in the United States, and MAP Pharmaceuticals' orally-inhaled Levadex will earn approximately $400 million in combined sales by 2018 in the migraine drug market. The Pharmacor 2010 finding from the topic entitled...

2010-01-11 06:30:00

MOUNTAIN VIEW, Calif., Jan. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The...

2009-12-01 06:00:00

MOUNTAIN VIEW, Calif., Dec. 1 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Alan Petro to the newly created position of Vice President, Manufacturing and Technical Operations. In his new role, Mr. Petro will lead the company's efforts in the area of product/process development and manufacturing in order to prepare for the potential commercialization of the company's lead product candidate, LEVADEX(TM) orally inhaled migraine therapy....

2009-10-29 06:00:00

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's Phase 3 FREEDOM 301 clinical trial with its LEVADEX(TM) orally inhaled migraine therapy. To date, more than 400 patients have completed at least six months of treatment and over 7,800 headaches have been treated in the safety extension. No drug-related serious...

2009-10-28 14:52:29

Editorial: Migraine with aura and increased risk of ischemic stroke Migraine with aura (temporary visual or sensory disturbances before or during a migraine headache) is associated with a twofold increased risk of stroke, finds a study published on bmj.com today. Further risk factors for stroke among patients with migraine are being a woman, being young, being a smoker, and using oestrogen containing contraceptives. The risk was highest among young women with migraine with aura who smoke and...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related